Aldeyra is conducting Phase 3 clinical trials of reproxalap, our lead investigational RASP inhibitor, in dry eye disease and allergic conjunctivitis. In addition, we have begun enrollment in a Phase 3 clinical trial of ADX-2191 in proliferative vitreoretinopathy.
The links below will take you to information about these studies on clinicaltrials.gov. Medical professionals can also email for more information about clinical trial participation.
![](https://www.aldeyra.com/wp-content/uploads/2019/09/woman-inserting-eye-drops-into-her-eye-picture-id456748725-1.jpg)
CLINICAL TRIAL
Phase 3 TRANQUILITY-2 Trial for Dry Eye Disease
A Multi-Center Randomized, Double-Masked, Parallel Design, Vehicle-Controlled Phase 2/3 Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
![](https://www.aldeyra.com/wp-content/uploads/2019/09/detailed-macro-of-blue-woman-human-eye-picture-id1010040498.jpg)
CLINICAL TRIAL
Phase 3 INVIGORATE Trial for Allergic Conjunctivitis
A Randomized, Double-Masked, Crossover Design, Vehicle-Controlled Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
Learn More![Surgeons working on a patient](https://www.aldeyra.com/wp-content/uploads/2019/08/cataract-surgery-picture-id155437078-e1584632291165.jpg)
CLINICAL TRIAL
Phase 3 GUARD Trial for Proliferative Vitreoretinopathy
A Multi-Center, Randomized, Controlled, Adaptive Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 for the Prevention of Proliferative Vitreoretinopathy